Nhwa pharmaceutical gets approvals for pain management drug

Jiangsu Nhwa Pharmaceutical Co., Ltd. announced on September 19, 2025, that it has obtained drug registration certificates from the National Medical Products Administration for its Tapentadol Hydrochloride tablets in 50mg, 75mg, and 100mg dosages. These approvals authorize the domestic production of these chemical drugs, classified as Category 3, with validities until September 15, 2030.

Tapentadol Hydrochloride tablets are indicated for treating severe acute pain in adults requiring opioid analgesia and for acute pain not adequately managed by alternative treatments. This marks a significant expansion of the company's product line in central nervous system analgesia.

The company anticipates that the market launch and sales of these tablets will positively impact its future performance and enhance its competitiveness. However, Jiangsu Nhwa Pharmaceutical also cautioned investors about potential uncertainties during the production and sales initiation phases, advising prudent decision-making and risk awareness.